BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of diseases that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.
BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative diseases and a potential treatment for complete Spinal Cord Injuries.
Our main research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. Today there are no treatments that can stop or slow down the progression of these diseases. We are also developing a potential treatment for patients affected by complete Spinal Cord Injury and for whom no treatment is currently available.